ALS Untangled No. 20: The Deanna Protocol

References

• http://www.cbn.com/cbnnews/healthscience/2012/November/Deanna-Protocol-a-Breakthrough-for-Lou-Gehrigs/.
   Google Scholar
• Berg JM, Tymoczko JL, Stryer L. In: Freeman WH, editor. Biochemistry: 5th edn. New York: 2002.
   Google Scholar
• Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329: 2002–12.
   PubMed Web of Science ®Google Scholar
• Liu Y, Lange R, Langansky J, Hamma T, Yang B, Steinacker JM. Improved training tolerance by supplementation with alpha-keto acids in untrained young adults: a randomized, double-blind, placebo-controlled trial. J Int Soc Sports Nutr. 2012;9:37.
   PubMedGoogle Scholar
• Hammarqvist F, Wernerman J, von der Decken A, Vinnars E.Alpha-ketoglutarate preserves protein synthesis and free glutamine in skeletal muscle after surgery. Surgery. 1991;109:28–36.
   PubMed Web of Science ®Google Scholar
• Joyner MJ. Glutamine and arginine: immunonutrients and metabolic modulators?Exerc Sport Sci Rev. 2005;33: 105–6.
   PubMedGoogle Scholar
• Carbone C, Pignatello R, Musumeci T, Puglisi G. Chemical and technological delivery systems for idebenone: a review of literature production. Expert Opin Drug Deliv. 2012;9: 1377–92.
   PubMed Web of Science ®Google Scholar
• Foerster BR, Callaghan BC, Petrou M, Edden RAE, Chenevert TL, Feldman EL. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology. 2012;78:1596–600.
   PubMed Web of Science ®Google Scholar
• D’Alessandro G, Calcagno E, Tartari S, Rizzardini M, Invernizzi R, Cantoni L. Glutamate and glutathione interplay in a motor neuronal model of amyotrophic lateral sclerosis reveals altered energy metabolism. Neurobiol Dis. 2011;43:346–55.
   PubMedGoogle Scholar
• Martin LJ. Mitochondrial pathobiology in ALS. J Bioenerg Biomembr. 2011;43:569–79.
   PubMedGoogle Scholar
• Swerdlow RH, Parks J, Cassarino D, Trimmer P, Miller S, Maguire D, et al. Mitochondria in sporadic amyotrophic lateral sclerosis. Exp Neurol. 1998;153:135–42.
   PubMed Web of Science ®Google Scholar
• Tieu K, Perier C, Caspersen C, Teismann P, Wu DC, Yan SD, et al. D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson’s disease. J Clin Invest. 2003;112:892–901.
   PubMed Web of Science ®Google Scholar
• Redler RL, Dokholyan NV.The complex molecular biology of amyotrophic lateral sclerosis (ALS). Prog Mol Biol Transl Sci. 2012;107:215–62.
   PubMed Web of Science ®Google Scholar
• Cleveland DW, Rothstein J. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806–19.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, et al. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology. 1996;47(Suppl 4):S242–50.
   Google Scholar
• Petri S, Korner S, Kiaei M. Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS. Neurol Res Int. 2012;2012:878030.
   PubMedGoogle Scholar
• Borg J, London J.Copper/zinc superoxide dismutase overexpression promotes survival of cortical neurons exposed to neurotoxins in vitro. J Neurosci Res. 2002;70:180–9.
   PubMedGoogle Scholar
• Personal communication with Dominic D’Agostino, Department of Molecular Pharmacology and Physiology at the University of Southern Florida.
   Google Scholar
• Zhao Z, Lange D, Voustianiouk A, MacGrogan D, Ho L, Suh J, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29.
   PubMed Web of Science ®Google Scholar
• Matthews RT, Yang L, Browne S, Bajk M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci U S A. 1998;95:8892–7.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 1999;5:347–50.
   PubMed Web of Science ®Google Scholar
• Kaufmann P, Thompson JL, Levy G, Buschsbaum R, Shefner J, Krivickas L, et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol. 2009;66:235–44.
   PubMed Web of Science ®Google Scholar
• Pastula DM, Moore DH, Bedlack RS. Creatine for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database of Systematic Reviews. 2012;12:1–27.
   PubMedGoogle Scholar
• Ghoddoussi F, Galloway MP, Jambekar A, Bame M, Needleman R, Brusilow WS. Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and glutamate in a mouse model of ALS. J Neurol Sci. 2010; 290:41–7.
   PubMed Web of Science ®Google Scholar
• Ghadge GD, Slusher B, Bodner A, Dal Canto M, Wozniak K, Thomas A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A. 2003;100:9554–9.
   PubMed Web of Science ®Google Scholar
• Wang R, Zhang D. Memantine prolongs survival in an amyotrophic lateral sclerosis mouse model. Eur J Neurosci. 2005;22:2376–80.
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Sarjubhai P, Melissa R, Haenggeli C, Huang Y, Bergles D, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73–7.
   PubMed Web of Science ®Google Scholar
• Verstraete E, Veldink J, Huisman M, Draak T, Uijtendaal E, van der Kooi A, et al. Lithium lacks effect on survival in amyotrophic lateral sclerosis: a phase IIb randomized sequential trial. J Neurol Neurosurg Psychiatry. 2012;83:557–64.
   PubMed Web of Science ®Google Scholar
• http://www.alsworldwide.org/ceftriaxone.html.
   Google Scholar
• de Carvalho M, Pinto S, Costa J, Evangelista T, Ohana B, Pinto A.A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11:456–60.
   PubMed Web of Science ®Google Scholar
• Ryberg H, Askmark H, Persson L. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand. 2003;108:1–8.
   PubMed Web of Science ®Google Scholar
• Miller RG, Moore DH, Gelinas D, Dronsky V, Mendoza M, Barohn R, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843–8.
   PubMed Web of Science ®Google Scholar
• Krochmal R, Hardy M, Bowerman S, Lu Q, Wang H, Elashoff R, Heber D. Phytochemical assays of commercial botanical dietary supplements, eCAM. 2004;1:305–13.
   Google Scholar
• http://www.iom.edu/Activities/Nutrition/SummaryDRIs/˜/media/Files/Activity%20Files/Nutrition/DRIs/5_Summary%20Table%20Tables%201-4.pdf
   Google Scholar